Axsome Therapeutics, Inc. (AXSM) financial statements (2021 and earlier)

Company profile

Business Address 22 CORTLANDT STREET, 16TH FLOOR
NEW YORK, NY 10007
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments184220143437
Cash and cash equivalents184220143437
Other undisclosed current assets00111
Total current assets:184220153538
Noncurrent Assets
Operating lease, right-of-use asset2 
Property, plant and equipment00000
Other noncurrent assets00000
Total noncurrent assets:20000
TOTAL ASSETS:186221153638
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1714545
Accounts payable1411434
Accrued liabilities 1101
Employee-related liabilities32111
Interest and dividends payable0    
Debt 3330
Other undisclosed current liabilities78242
Total current liabilities:232411127
Noncurrent Liabilities
Long-term debt and lease obligation4917479
Long-term debt, excluding current maturities4817479
Operating lease, liability1 
Other undisclosed noncurrent liabilities(1)    
Total noncurrent liabilities:4917479
Total liabilities:7242141917
Stockholders' equity
Stockholders' equity attributable to parent11417911722
Common stock00000
Additional paid in capital3933551089369
Accumulated deficit(279)(176)(108)(77)(48)
Total stockholders' equity:11417911722
TOTAL LIABILITIES AND EQUITY:186221153638

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(99)(67)(33)(27)(28)
Operating loss:(99)(67)(33)(27)(28)
Nonoperating expense
(Investment Income, Nonoperating)
(3)(1)(1)(1)(0)
Interest and debt expense(2)    
Loss before gain (loss) on sale of properties:(103)(68)(34)(29)(28)
Other undisclosed net income103  
Net loss:(103)(68)(31)(29)(28)
Other undisclosed net income (loss) attributable to parent   (0)0
Net loss available to common stockholders, diluted:(103)(68)(31)(29)(27)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(103)(68)(31)(29)(28)
Comprehensive loss, net of tax, attributable to parent:(103)(68)(31)(29)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: